Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : HPV Vaccine,Inapplicable
Therapeutic Area : Oncology
Study Phase : Undisclosed
Recipient : Queen's University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
May 07, 2024
Lead Product(s) : HPV Vaccine,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Recipient : Queen's University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Doravirine,Lamivudine,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Recipient : University Health Network, Toronto
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 11, 2020
Lead Product(s) : Doravirine,Lamivudine,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Recipient : University Health Network, Toronto
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rocuronium Bromide,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Recipient : CIUSSS de l'Est-de-l'Île-de-Montréal
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 10, 2019
Lead Product(s) : Rocuronium Bromide,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Recipient : CIUSSS de l'Est-de-l'Île-de-Montréal
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sugammadex Sodium,Inapplicable
Therapeutic Area : Sleep
Study Phase : Phase IV
Recipient : University Health Network, Toronto
Deal Size : Inapplicable
Deal Type : Inapplicable
Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery and Complications
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 20, 2018
Lead Product(s) : Sugammadex Sodium,Inapplicable
Therapeutic Area : Sleep
Highest Development Status : Phase IV
Recipient : University Health Network, Toronto
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Human Papillomavirus 9-valent Vaccine, Recombinant,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Recipient : University of British Columbia
Deal Size : Inapplicable
Deal Type : Inapplicable
Long Term Immune Memory Responses to HPV Vaccination Following 2 vs 3 Doses of Quad-HPV Vaccine
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
November 18, 2016
Lead Product(s) : Human Papillomavirus 9-valent Vaccine, Recombinant,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Recipient : University of British Columbia
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
